- Home
- CATX vs TVRD Comparison
CATX vs TVRD Comparison
Compare CATX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- TVRD
- Stock Information
- Founded
- CATX 1983
- TVRD 2017
- Country
- CATX United States
- TVRD United States
- Employees
- CATX N/A
- TVRD N/A
- Industry
- CATX Medical/Dental Instruments
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- TVRD Health Care
- Exchange
- CATX Nasdaq
- TVRD Nasdaq
- Market Cap
- CATX 239.0M
- TVRD 246.5M
- IPO Year
- CATX N/A
- TVRD N/A
- Fundamental
- Price
- CATX $2.08
- TVRD $3.93
- Analyst Decision
- CATX Strong Buy
- TVRD Buy
- Analyst Count
- CATX 11
- TVRD 7
- Target Price
- CATX $11.73
- TVRD $51.67
- AVG Volume (30 Days)
- CATX 2.0M
- TVRD 194.5K
- Earning Date
- CATX 11-10-2025
- TVRD 11-13-2025
- Dividend Yield
- CATX N/A
- TVRD N/A
- EPS Growth
- CATX N/A
- TVRD N/A
- EPS
- CATX N/A
- TVRD N/A
- Revenue
- CATX $1,075,000.00
- TVRD N/A
- Revenue This Year
- CATX N/A
- TVRD N/A
- Revenue Next Year
- CATX N/A
- TVRD N/A
- P/E Ratio
- CATX N/A
- TVRD N/A
- Revenue Growth
- CATX N/A
- TVRD N/A
- 52 Week Low
- CATX $1.60
- TVRD $3.78
- 52 Week High
- CATX $5.39
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- CATX 32.16
- TVRD 21.55
- Support Level
- CATX $2.00
- TVRD $3.87
- Resistance Level
- CATX $2.54
- TVRD $4.20
- Average True Range (ATR)
- CATX 0.20
- TVRD 0.30
- MACD
- CATX 0.02
- TVRD 0.95
- Stochastic Oscillator
- CATX 19.51
- TVRD 18.99
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.